Anthony Heaney, MD
Endocrinology, Diabetes & Metabolism · Los Angeles, CANPI 1720016850
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $394,972 of the $587,653 with a category attached, or 67.2%. 16 manufacturers reported payments, led by Corcept Therapeutics at 32.8% of the total. 2025 is the largest year on record at $200,866, 9.9 times the $20,384 reported in 2019. Among endocrinology, diabetes & metabolism clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 503 payments — averaging $1168.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$193K
- Novo Nordisk$156K
- Amryt Pharma Holdings Ltd$86K
- Recordati_rare_diseases_inc.$69K
- Chiesi USA, Inc.$31K
- Chiasma, Inc.$27K
- plus $26K from 10 others
Across 34 payments — averaging $7223.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Strongbridge US Inc.$94K
- Ascendis Pharma Endocrinology Inc$72K
- Amryt Pharma Holdings Ltd$39K
- Corcept Therapeutics$16K
- Xeris Pharmaceuticals, Inc.$12K
- Pfizer$7K
- plus $6K from 1 others
What the payments were for
- Consulting fees$89,58015%
- Speaking & faculty fees$394,97267%
- Travel & lodging$91,62116%
- Food & beverage$11,4122%
- Education$680%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 178 | $192,780 |
| Novo Nordisk | 122 | $155,664 |
| Amryt Pharma Holdings Ltd | 68 | $85,793 |
| Recordati_rare_diseases_inc. | 51 | $69,296 |
| Chiesi USA, Inc. | 32 | $30,981 |
| Chiasma, Inc. | 21 | $27,450 |
| Ipsen Biopharmaceuticals, Inc | 17 | $14,416 |
| Ascendis Pharma Endocrinology Inc | 1 | $3,376 |
| Xeris Pharmaceuticals, Inc. | 4 | $2,642 |
| Progenics Pharmaceuticals, Inc. | 1 | $1,842 |
| H. Lundbeck A S | 1 | $1,200 |
| Sun Pharmaceutical Industries Inc. | 1 | $1,016 |
| Tolmar, Inc. | 3 | $603 |
| Novo Nordisk US Research & Development, Inc. | 1 | $500 |
| Pfizer | 1 | $76 |
| Curium US LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$190,235
- MYCAPSSA$142,786
- Sogroya$124,864
- ISTURISA$60,224
- Macrilen$19,433
- SOMATULINE DEPOT$14,356
- Norditropin$9,425
- OSILODROSTAT$8,485
- SKYTROFA$3,376
- AZEDRA$1,842
- BYNFEZIA PEN$1,016
- GVOKE PFS$160
- RECORLEV$133
How this compares
$587,653 in reported general payments places this provider in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SomavertPegvisomant | 46 | $738,877 |
| MycapssaOctreotide Acetate | 34 | $421,190 |
| Norditropin FlexproSomatropin | 13 | $153,801 |
| Sandostatin Lar DepotOctreotide Acetate,mi-Spheres | 12 | $82,273 |
| Somatuline DepotLanreotide Acetate | 12 | $69,431 |
| HumatropeSomatropin | 28 | $47,123 |
| SogroyaSomapacitan-Beco | 11 | $31,318 |
| Desmopressin Acetate | 61 | $6,996 |
| SynthroidLevothyroxine Sodium | 49 | $4,462 |
| Cabergoline | 53 | $3,888 |
| Testosterone | 41 | $3,594 |
| Hydrocortisone | 99 | $3,584 |
| Testosterone Cypionate | 34 | $1,490 |
| Levothyroxine Sodium | 115 | $1,294 |
| Prednisone | 31 | $235 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerSomavert | $76 | $738,87746 claims |
| Chiesi USA, Inc.Mycapssa | $30,981 | $421,19034 claims |
| Ipsen Biopharmaceuticals, IncSomatuline Depot | $14,416 | $69,43112 claims |
| Novo NordiskSogroya | $155,664 | $31,31811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Los Angeles
- Christian GastelumLos Angeles$321K
- Shlomo MelmedLos Angeles$177K
- Sina TebiLos Angeles$133K
- Glenn BraunsteinLos Angeles$113K
- Laurence KatznelsonLos Angeles$99K
- John CarmichaelLos Angeles$90K
- Peter ButlerLos Angeles$58K
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.